Zydus gets USFDA ‘nod’ for transfusion drug

Drug firm Zydus Cadila said it has got tentative nod from the U.S. health regulator to market Deferasirox tablets for oral suspension. “Zydus Cadila has received the tentative approval from USFDA to market Deferasirox tablets for oral suspension (Exjade tablets) in the strengths of 125 mg, 250 mg and 500 mg,” the company said in a statement. The tablet is used to treat high levels of iron in the body caused by multiple blood transfusions.PTI

Source: Read Full Article